Efficacy News and Research

RSS

New Kaiser Family Foundation tool shows which global health interventions are working

Today, the Kaiser Family Foundation unveiled an innovative, online tool that allows users to learn quickly and easily about which global health interventions work. The Global Health Intervention Review (GHIR) compiles the latest information on the efficacy of key global health interventions, including the strength of the evidence, and presents the information in a variety of accessible formats. Users can view a comprehensive overview and a key findings table.

2 Jun 2011

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced financial results and achievements for the quarter ended March 31, 2011.

2 Jun 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO Pharmaceuticals, Inc., today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma.

2 Jun 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO Pharmaceuticals, Inc. today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib in Asian subjects with non-small cell lung cancer.

2 Jun 2011

SHEA, ASGE update Flexible gastrointestinal endoscope guideline

The American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Healthcare Epidemiology of America (SHEA) have updated their 2003 joint guideline for reprocessing gastrointestinal endoscopes to reaffirm reprocessing methods and take into account evolved technology and disinfection systems.

2 Jun 2011

Positive results from Nuvilex European Phase II trial against pancreatic cancer

Nuvilex, Inc. announces the favorable results of a completed Phase II clinical trial carried out in Europe against pancreatic cancer. The treatment technology used in this trial was recently acquired by Nuvilex.

2 Jun 2011

IMS Model to guide providers and patients toward adherence

Physicians can help their patients follow prescribed treatments and achieve healthier results - particularly in chronic disease management - by using a three-pronged strategy developed by a team of researchers from the University of California, Riverside, Texas State University-San Marcos, and La Sierra University in Riverside, Calif.

2 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Adaptimmune announced that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy.

1 Jun 2011

Scientists discover key biological mechanism underpinning transition to alcohol dependence

A team of Scripps Research Institute scientists has found a key biological mechanism underpinning the transition to alcohol dependence. This finding opens the door to the development of drugs to manage excessive alcohol consumption.

1 Jun 2011

Diamyd European Phase III study in diabetes does not meet primary endpoint

Diamyd Medical AB reports that the Company has decided not to complete the follow-up period of a European Phase III study with the antigen-based therapy Diamyd.

1 Jun 2011

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

CrystalGenomics, Inc. and CG Pharmaceuticals, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced that the first patient has been enrolled for a Phase 2b clinical study of CG100649, CrystalGenomics' clinical stage novel NSAID candidate, in patients with knee or hip osteoarthritis.

1 Jun 2011

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it received ethics board approval for a Phase 1B clinical trial in Australia of its biologic anti-inflammatory agent, Ampion.

1 Jun 2011

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

YM BioSciences Inc., today announced that it has received positive opinions from the Committee for Orphan Medicinal Products of the European Commission to grant Orphan Medicinal Product Designation to its JAK1/JAK2 inhibitor, CYT387, for the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

31 May 2011

Radiant to expand consumer products testing capabilities

Radiant Research, Inc. today announced that it is expanding its consumer products testing capabilities through creation of a new division of Radiant Research devoted to consumer trial conduct.

31 May 2011

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational agent peginesatide for the treatment of anemia associated with chronic renal failure in adult patients on dialysis.

31 May 2011

YM announces updates on nimotuzumab clinical development program

YM BioSciences Inc., today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for nimotuzumab at the 2011 Annual Meeting of the American Society of Clinical Oncology.

31 May 2011

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

UCB today announced data which showed that the addition of Cimzia to current therapy was associated with a rapid and consistent clinical response in a diverse group of rheumatoid arthritis (RA) patients.

30 May 2011

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

The U.S. Food and Drug Administration today approved Dificid tablets for the treatment of Clostridium difficile-associated diarrhea.

30 May 2011

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zocor.

29 May 2011

Efficacy News and Research

New Kaiser Family Foundation tool shows which global health interventions are working

Protox reports net and comprehensive loss of $2.2 million for first quarter 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

SHEA, ASGE update Flexible gastrointestinal endoscope guideline

Positive results from Nuvilex European Phase II trial against pancreatic cancer

IMS Model to guide providers and patients toward adherence

PCF funds 14 new Creativity Awards for advanced prostate cancer research

Adaptimmune announces opening of Phase I/II clinical trial in multiple myeloma

Scientists discover key biological mechanism underpinning transition to alcohol dependence

Diamyd European Phase III study in diabetes does not meet primary endpoint

CrystalGenomics begins enrollment in CG100649 Phase 2b osteoarthritis study

Ampio commences new anti-inflammatory agent Phase 1B trial in osteoarthritis

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

Radiant to expand consumer products testing capabilities

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

YM announces updates on nimotuzumab clinical development program

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

Optimer receives FDA approval for Dificid tablets to treat C. difficile-associated diarrhea

Efficacy of Abbott cholesterol drug in question

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News